Key Highlights

  • Shares fell 6.47% pre-market to $8.82, pulling back from a prior close of $9.43.
  • The company was granted a Hong Kong Patent covering the core technology behind its flagship lung cancer diagnostic.
  • The patent adds to a 2025 grant in China, giving the company dual protection across two Asian markets.
  • Asia accounts for an estimated 1.6 million new lung cancer cases diagnosed annually.
  • Market Capitalization stands at approximately $11.00 million.

New Patent Strengthens Asia Positioning Despite the Pre-Market Slide

bioAffinity Technologies (NASDAQ:BIAF) shares are trading lower in pre-market action even after the company announced a new intellectual property win in Asia. The Hong Kong Intellectual Property Department granted a patent covering the company's proprietary platform technology, which uses flow cytometry and fluorescent markers to characterize cell populations in sputum for lung cancer risk assessment. bioAffinity is a San Antonio-based biotechnology company focused on noninvasive detection of early-stage lung disease, with its diagnostic test serving as its primary commercial product.

The newly granted patent complements a 2025 patent secured in China, giving the company protection across two jurisdictions in a region that carries a substantial share of the global lung cancer burden. Company Leadership framed the filing as strengthening its position to enter the broader Asian market.

Diagnostic Technology Rests on Clinical Performance Data

The patented technology underlies the company's core diagnostic, which is designed to assess the likelihood of malignancy in small lung nodules identified through low-dose CT scans. In a published clinical trial, the test demonstrated high sensitivity and specificity, along with a high negative predictive value, in high-risk patients with small indeterminate nodules. The test is marketed as a laboratory developed test and is intended to be used alongside other clinical findings rather than as a standalone diagnostic tool.

Pre-Market Pullback Runs Counter to the Positive Headline

The pre-market decline stands in contrast to the nature of the announcement, which extends the company's intellectual property estate rather than introducing any negative development. The move may reflect broader profit-taking or sentiment-driven trading rather than a reaction to the patent news itself, though no company-specific negative catalyst accompanied the release.

Expanding Patent Estate Sets Up the Next Commercial Push

bioAffinity's global patent estate now spans multiple jurisdictions beyond Hong Kong and China, including the United States, Australia, Canada, the European Union, Japan, Mexico and Singapore. The broader intellectual property protection is intended to support the company's commercial expansion as it looks to grow adoption of its diagnostic platform both domestically and internationally.